Continental (ETR:CON) received a €246.00 ($292.86) price objective from equities researchers at Societe Generale in a research report issued to clients and investors on Wednesday. The brokerage presently has a “buy” rating on the stock. Societe Generale’s target price would indicate a potential upside of 8.27% from the stock’s previous close.
Stocks under $10 can be a cost-effective way for the little guy to diversify a portfolio, especially if you don’t have a lot of money left over to invest after you pay bills and pad your emergency fund. However, many low-priced stocks are priced low for a reason, so you need to pick stocks under $10 that have a good shot at turning into stocks over $10 in the not-too-distant future. Is....More>>>
The big pharma company ranked as the best performer among its peers in 2017, with an impressive gain of 54%. AbbVie started off 2018 great as well. However, disappointing results from a phase 2 clinical study of cancer drug Rova-T caused the stock to skid.
Still, AbbVie’s top executives remain very optimistic about the company’s....More>>>
Healthcare products tend to remain in demand no matter what is going on in the global economy. That’s why the sector is a great place to hunt for high-quality investments.
So which stocks do our healthcare experts have their eye on right now? We asked these three Motley Fool investors to weigh in, and they pickedAbbVie (NYSE:ABBV),Cardinal Health (NYSE:CAH), and Masimo (NASDAQ:MASI).
Cheviot Value Management LLC cut its stake in shares of AbbVie Inc. (NYSE:ABBV) by 8.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 55,818 shares of the company’s stock after selling 5,054 shares during the quarter. AbbVie comprises approximately 2.8% of Cheviot Value Management LLC’s investment....More>>>
Chinese banks in two cities are testing a custom-built digital currency developed by the Peoples Bank of China, according to information gleaned from local media reports and interviews with two individuals who are familiar with the central banks thinking.
The digital currency, known to the broader world as ChinaCoin, but officially referred to inside China as digital renminbi, or RMB, was....More>>>
Incremental games, which are also known as idle games, idle tapper games, clicker games or clicking games, are an increasingly popular video game genrewhose gameplay consists of the player performing simple actions (such as clicking on the screen) repeatedly to gain currency. This currency can then be used to obtain items or abilities that increase the rate at which currency accrues.
Amgen (NASDAQ:AMGN) and Biogen (NASDAQ:BIIB) have a lot in common. They are both hugely successful biotech giants that were founded decades ago. They each have produced stellar returns for their long-term shareholders and crank out copious amounts of cash flow each year.
Zurcher Kantonalbank Zurich Cantonalbank lowered its position in AbbVie Inc (NYSE:ABBV) by 14.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 362,286 shares of the company’s stock after selling 58,882 shares during the period. Zurche
Shares of Voyager Therapeutics (NASDAQ:VYGR) were skyrocketing 21.7% higher as of 11:22 a.m. EST on Friday. The small biotech announced a collaboration with AbbVie (NYSE:ABBV) to develop vectorized antibodies to treat Parkinson's disease and other diseases characterized by the abno
If there was a "Bad News Bears" team of biotechs, Celgene (NASDAQ:CELG) and Gilead Sciences (NASDAQ:GILD) would probably be the star players. Both Celgene and Gilead have experienced more than their fair share of bad news over the last couple of years.